Table 1.
Characteristics of the included patients at the start of sirolimus treatment.
| Patient characteristics | Mean (range) or % |
|---|---|
| All (n = 27) | |
| Background variables | |
| Females | 100 |
| Age (years) | 44.3 (20–65) |
| Duration of SLE (years) | 9.8 (2–34) |
| Weight (kg) | 65.6 (47–93) |
| Length (cm) | 165.7 (147–176) |
| Caucasian ethnicity | 100 |
| cSLEDAI (score) | 4.5 (1–12) |
| PGA (score) | 1.3 (0–2) |
| SDI (score) | 1.0 (0–6) |
| Number of fulfilled ACR criteria | 5.5 (4–8) |
| Concomitant medication | |
| Prednisolone, daily dose (mg) | 7.5 (0–20) |
| Hydroxychloroquine | 59.2 |
| Methotrexate | 7.4 |
| Mycophenolate mofetil | 11.1 |
| Warfarin | 14.8 |
| Acetylsalicylic acid | 29.6 |
| Statins | 0 |
| Clinical phenotypes (ACR-82 definitions) | |
| (1) Malar rash | 48.1 |
| (2) Discoid rash | 18.5 |
| (3) Photosensitivity | 63.0 |
| (4) Oral ulcers | 22.2 |
| (5) Arthritis | 100 |
| (6) Serositis | 48.1 |
| (a) Pleuritis | 48.1 |
| (b) Pericarditis | 3.7 |
| (7) Renal disorder | 25.9 |
| (8) Neurologic disorder | 3.7 |
| (a) Seizures | 3.7 |
| (b) Psychosis | 0 |
| (9) Hematologic disorder | 66.7 |
| (a) Hemolytic anemia | 3.7 |
| (b) Leukocytopenia | 37.0 |
| (c) Lymphocytopenia | 44.4 |
| (d) Thrombocytopenia | 14.8 |
| (10) Immunologic disorder | 51.9 |
| (a) Anti-dsDNA antibody | 44.4 |
| (b) Anti-Smith antibody | 7.4 |
| (11) IF-ANA | 100 |
ACR, American College of Rheumatology; IF-ANA, immunofluorescence microscopy antinuclear antibodies; cSLEDAI-2K, clinical Systemic lupus erythematosus disease activity index 2000; SDI, SLICC/ACR damage index.